Catechin ((+)-Catechin) |
Catalog No.GC32841
One-Click Copy Product Info
|
카테킨((+)-카테킨)((+)-카테킨((+)-카테킨))은 1.4 μ의 IC50으로 사이클로옥시게나제-1(COX-1)을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 154-23-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Catechin inhibits cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM.
Catechin exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC50 of 1.4 μM[1]. A dose-dependent reduction in color is observed after 24 hours of treatment with Catechin, and 54.76% of the cells are dead at the highest concentration of Catechin tested (160 μg/mL) whereas the IC50 of Catechin is achieved at 127.62 μg/mL Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL Catechin, respectively, undergo apoptosis. The expression levels of Caspase-3, -8, and -9 and p53 in MCF-7 cells treated with 150 μg/mL Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells[2].
Animals treated with Catechin at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively)[3].
[1]. Waffo-Téguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer. 2001;40(2):173-9. [2]. Alshatwi AA. Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis. J Exp Clin Cancer Res. 2010 Dec 17;29:167. [3]. Cheruku SP, et al. Catechin ameliorates doxorubicin-induced neuronal cytotoxicity in in vitro and episodic memory deficit in in vivo in Wistar rats. Cytotechnology. 2018 Feb;70(1):245-259.
|
Cell experiment: |
The Cell viability assay is performed to assess the toxicity of different concentrations of Catechin on MCF-7 cells. Briefly, MCF-7 cells (2×104 cells/well) are plated in 96-well plates and treated with 0 μg/mL Catechin and 160 μg/mL Catechin for 24 hours. Then, 40 μL of the Cell Titer Blue solution is directly added to the wells and incubated at 37°C for 6 hours. The fluorescence is recorded with a 560 nm/590 nm (excitation/emission) filter set using a microplate fluorescence reader, and the IC50 is calculated. Quadruplet samples are run for each concentration of Catechin in three independent experiments[2]. |
|
Animal experiment: |
Rats[3]Twelve weeks old, healthy male rats weighing 200 to 230 g are used in this study. Rats are divided into four experimental groups (n=9 each) for one vehicle and three groups of Catechin (three doses). The doses of Catechin are prepared at 50, 100, 200 mg/kg in 0.25% w/v sodium carboxy methylcellulose (CMC) and administered orally for 7 days prior to and during the experimental trials. Episodic memory, the conscious memory of the past experiences is evaluated in this study[3]. |
|
References: [1]. Waffo-Téguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer. 2001;40(2):173-9. |
|
| Cas No. | 154-23-4 | SDF | |
| Canonical SMILES | O[C@@H]1[C@@H](C2=CC(O)=C(O)C=C2)OC3=CC(O)=CC(O)=C3C1 | ||
| Formula | C15H14O6 | M.Wt | 290.27 |
| Solubility | DMSO : ≥ 100 mg/mL (344.51 mM) | Storage | 4°C, away from moisture and light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4451 mL | 17.2253 mL | 34.4507 mL |
| 5 mM | 689 μL | 3.4451 mL | 6.8901 mL |
| 10 mM | 344.5 μL | 1.7225 mL | 3.4451 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)